55 research outputs found
Biochemical and pharmaceutical traits of Marrubium vulgare L. plants treated with plant growth-promoting bacteria and elevated CO2
No full textThe present research aimed to understand the influence of plant growth-promoting bacteria (PGPB) on various biochemical, nutritional, and pharmaceutical characteristics of Marrubium vulgare plants grown under elevated carbon dioxide (eCO(2)). To achieve this objective, a pot experiment was carried out, consisting of two treatments, namely: (i) biofertilization (Bf) by a PGPB strain (Micromonospora sp.) and (ii) two different air CO2 levels, including ambient CO2 (aCO(2)) and eCO(2) concentrations (410 and 710 mu mol CO2 mol(-1), respectively). The improvement in the photosynthesis rate of eCO(2) and Bf-treated plants can explain the increase in the production of carbohydrate. This is evidenced by a substantial rise, reaching up to + 75% and 25% in the total sugar and starch content in plants subjected to eCO(2) treatment, respectively. Additionally, eCO(2)-treated plants exhibited a remarkable 102% increase in soluble sugar synthesis, while plants subjected to Bf treatment showed a notable increase of 66%. Such modifications could be the main factor affecting plants carbon and nitrogen metabolism. Although the level of certain amino acids (such as glycine, tyrosine, and phenylalanine) in plants exhibited significant increases in response to eCO(2) and Bf, the levels of other amino acids demonstrated enhancements in plants grown under eCO(2) (e.g., histidine) or under treatments containing Bf (e.g., alanine and ornithine). Improvements in primary metabolites led to more benefits in plants treated with Bf and CO2 by boosting secondary metabolites accumulation, including phenolics (+ 27-100%), flavonoids (+ 30-92%), and essential oils (up to + 296%), as well as improved antioxidant capacity (FRAP). This remarkable effectiveness was evident in the significant increase in the biomass production, highlighting the synergistic impact of the treatments. Therefore, the interaction of Bf and eCO(2) not only induced plant biomass accumulation but also improved the nutritional and pharmaceutical value of M. vulgare plants
Gastrointestinal manifestations in children with primary immunodeficiency diseases
No full textNo Abstrac
Race and Criminal Justice in Canada: An Overview
No full textCanadian Law and Society Association Annual Meeting 2014. University of Manitoba, Faculty of Law, Winnipeg, M
The importance of vaccination and immunoglobulin treatment for patients with primary immunodeficiency diseases (PIDs) ‐ World PI Week April 22–29, 2015
No full textLa importancia de la vacunación y el tratamiento con inmunoglobulina para pacientes con inmunodeficiencias primarias
No full textLas inmunodeficiencias primarias son un grupo heterogéneo de enfermedades genéticas raras
que afectan el desarrollo o el funcionamiento de la inmunidad innata o la adaptativa. La mayoría de los pacientes que las padecen tienen mayor susceptibilidad a infecciones tanto comunes como raras, a veces con desenlace fatal. Por lo tanto es esencial ofrecer tratamiento rápido y eficaz para prevenir infecciones, proporcionando programas de vacunación adecuados
y administrando regularmente el tratamiento con inmunoglobulina G (IgG) de reemplazo, en
los trastornos con defecto en la producción o funcionamiento de los anticuerpos. En algunas
condiciones también está indicada la quimioprofilaxis con antibióticos y antifúngicos
Antinucleosome antibodies as early predictors of lupus nephritis
No full textBackground: The role of the nucleosome in the induction of antibody response in lupus mediated tissue damage especially glomerulonephritis, may provide a new insight in the early diagnosis and alternative therapeutic developments in systemic lupus erythematosus (SLE). Objectives: To evaluate the frequency and specificity of antinucleosome antibody expression in SLE patients in relation to disease activity. Also, to assess their predictive value in subclinical lupus nephritis. Methods: This study included 26 patients with SLE and 52 control subjects (26 were healthy and 26 had juvenile rheumatoid arthritis "JRA"). Among lupus patients, 15 had clinical evidence of renal involvement. After clinical evaluation to calculate the SLE disease activity index (SLEDAI), measurements of urinary microalbumin and serum antinucleosome antibodies (antinucleosome specific, antihistone and anti ds-DNA antibodies by ELISA) were performed. Patients without clinical evidence of renal involvement were followed up for one year and measurement of urinary microalbumin was repeated at the end of the study period. Those who later developed microalbuminurea were categorized as patients with subclinical lupus nephritis. Results: The expression of the 3 studied antinucleosome antibodies was significantly higher among lupus patients as compared to JRA patients and healthy controls. Seropositivity for one or more antinucleosome antibodies was elicited in 84.5% of lupus patients. Serum levels of the 3 antinucleosome antibodies were significantly higher among lupus patients with clinical nephritis than those without nephritis. ANSAb had higher sensitivity, specificity and positive and negative predictive values for subclinical lupus nephritis (100%) than antihistone and anti ds-DNA antibodies (43%, 100%, 100% and 50% respectively for either antibodies). All patients with lupus nephritis were seropositive for at least one of the antinucleosome antibodies, while those without clinical or subclinical nephritis were seronegative for the 3 antinucleosome antibodies. In 27.3% of patients with lupus nephritis, ANSAB was positive while both antihistone and ds-DNA antibodies were negative. Antinucleosome antibodies correlated positively with SLEDAI and cumulative steroid dose and negatively with corrected creatinine clearance. Conclusions: The observed sensitivity and specificity of antinucleosome specific antibodies as early indicators of subclinical lupus nephritis appear encouraging and deserve further analysis on a large scale in order to confirm their validity, especially in the anti ds-DNA seronegative lupus patients.Keywords: antinucleosome antibodies, antinucleosome specific antibodies, anti ds-DNA antibodies, antihistone antibodies, SLE, lupus nephritisEgypt J Pediatr Allergy Immunol 2005; 3(2):54-6
- …
